Ruth Calder
Enforcement Editor
Editorial role · not a licensed clinician
Ruth Calder covers enforcement for GLP Watchdog: FDA warning letters and untitled letters, state pharmacy-board licensing and disciplinary actions, 503A and 503B registration status, and the corporate-entity records that connect brands to the operators behind them.
Her work starts from primary documents. Every enforcement claim on this site is matched to a specific letter, registration record, or filing by company name AND address — never by name resemblance — and the recipient is identified from the document itself rather than from a seller's or a competitor's characterization of it. Where a claim rests on an absence (a seller is not registered, no action has been taken), that absence is established against a positive control, because a search that returns nothing is as often a broken search as a clean record.
The beat, the method and the sourcing standard described above are exactly what this work is held to. GLP Watchdog makes no claim that this author holds a clinical license, an academic post, a pharmaceutical-industry role, a patent, or any professional credential. There are none of those things behind this byline, and none is implied. What it stands behind is the documentary record cited in each piece, which a reader can pull independently.
She is not a licensed clinician and does not give medical advice. Clinical statements are sourced to FDA prescribing information, PubMed-indexed primary research, or named regulatory filings, and are labeled with what kind of evidence they rest on. GLP Watchdog is actively seeking a credentialed medical reviewer (MD, PharmD, NP); until one is retained, no article on this site carries a medical-review byline, because claiming a review that did not happen is the same failure as claiming a credential that does not exist.
GLP Watchdog is reader-supported through affiliate commissions on some provider links. Ruth's enforcement coverage is produced without reference to which sellers are commercial partners, and a partner has been flagged on this site. Where a piece concerns a company we earn from, that relationship is disclosed on the page itself, per row, and stated as a fact rather than a hedge. The full policy is at /disclosure; the scoring methodology is at /methodology.
Contact
Corrections and questions on this beat go straight to ruth@glpwatchdog.org. If a figure on this site is wrong, that address is the fastest way to get it changed, and every change is logged on our corrections page.
Subject expertise
- FDA warning letters
- FDA untitled letters
- Compounded medications regulation
- 503A compounding pharmacies
- 503B outsourcing facilities
- State pharmacy board licensing
- Telehealth regulation
- Counterfeit and gray-market pharmaceuticals
- Corporate entity research
- GLP-1 receptor agonists
How Ruth Calder reviews content for GLP Watchdog
That applies to every research article and every provider review: nothing publishes until it has been through the same structured verification pass. A clinical claim has to trace back to FDA prescribing information, to PubMed-indexed primary research, or to a named regulatory filing. Data about a seller is checked against the live page it came from, and price is checked again on a recurring cadence.
Read the full editorial process at /editorial-policy, the six-dimension scoring rubric at /methodology, the corrections policy at /corrections, and our affiliate disclosure at /disclosure.